Abstract
Thirty-three patients with malignant nondysgerminomatous germ cell tumors were treated with vincristine/dactinomycin/cyclophosphamide regimen. Thirty-two patients were suitable for analysis. The overall cure rate was 68.7%. This is comparable to the cure rate observed in the cisplatin/vinblastin/bleomycin regimen. The roles of second-look laparotomy in malignant germ cell tumor are discussed.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Dactinomycin / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
Ovarian Neoplasms / drug therapy*
-
Teratoma / drug therapy*
-
Vincristine / administration & dosage
Substances
-
Dactinomycin
-
Vincristine
-
Cyclophosphamide